MYRIAD GENETICS INC | 24,64 Euro | -0,06 -0,24 % | |
| WKN: 897518 ISIN: US62855J1043 Ticker-Symbol: MYD | Frankfurt | 24.05.13 | 12:12 Uhr |
Branche BiotechnologieAktienmarkt NASDAQ Biotech |
|
|
| Zeit | Aktuelle Nachrichten
Sprache: | Leser | Medien | |
|---|---|---|---|---|
| 00:19 | Myriad Genetics Shares Up 15.8% Since SmarTrend's Buy Recommendation | 2 | SmarTrend | |
| 24.05. | Look for Shares of Myriad Genetics to Potentially Rebound after Yesterday's 2.36% Sell Off | - | SmarTrend | |
| 24.05. | After Yesterday's Decline of 2.36%, Myriad Genetics Offers Investors Better Value | - | SmarTrend | |
| 22.05. | Myriad Genetics: Höhenflug dank Jolie | 18 | BILANZ | |
| 20.05. | Splicing & Dicing Myriad Genetics Amidst the Angelina Jolie Disclosure | 8 | Motley Fool | |
| 19.05. | Myriad Genetics: Disruptive Products For Cancer Diagnostics | 5 | Seeking Alpha | |
| 15.05. | Myriad Genetics: Strong Results Ahead Of Supreme Court Decision | 16 | Seeking Alpha | |
| 14.05. | Myriad Genetics shares rise to three-year highs | 6 | Yahoo-USA | |
| 14.05. | Shares of Myriad Genetics Has Risen Above Previous 52-Week High | 4 | SmarTrend | |
| 13.05. | Myriad Genetics: 52-Week High Recently Eclipsed | 5 | SmarTrend | |
| 12.05. | Myriad Genetics' CEO Hosts Annual Day (Transcript) | 19 | Seeking Alpha | |
| 08.05. | MYRIAD GENETICS INC - 10-Q, Quaterly Report | 1 | SEC Filings | |
| 08.05. | Upgrade Alert for Myriad Genetics | 7 | SmarTrend | |
| 08.05. | Myriad Genetics Boosts 2013 Outlook As Q3 Results Top Estimates; Shares Up 10% | 85 | AFX News | |
| WASHINGTON (dpa-AFX) - Diagnostic-testing company Myriad Genetics, Inc.
(MYGN) reported Tuesday a profit for the third quarter that increased 28 percent
from last year, reflecting double-digit... Mehr lesen zu: Myriad Genetics Boosts 2013 Outlook As Q3 Results Top Estimates; Shares Up 10% | ||||
| 08.05. | Myriad Genetics Management Discusses Q3 2013 Results - Earnings Call Transcript | 1 | Seeking Alpha | |
| 07.05. | Myriad Genetics Q3 Profit Up 28%, Lifts FY13 Outlook | 43 | AFX News | |
| WASHINGTON (dpa-AFX) - Myriad Genetics Inc. (MYGN) Tuesday reported
third-quarter profit of $37.9 million or $0.46 per share, up from $29.6 million
or $0.34 per share in same period last... Mehr lesen zu: Myriad Genetics Q3 Profit Up 28%, Lifts FY13 Outlook | ||||
| 25.04. | Possible Bullish Inside Day Candle Pattern Detected for Myriad Genetics | 1 | SmarTrend | |
| 22.04. | Myriad Genetics: Growth Stock, Hot Sector, Solid Industry | 13 | Seeking Alpha | |
| 13.04. | Myriad Genetics CEO Claims He Owns Your Genes | 19 | Forbes | |
| 10.04. | Myriad Genetics Crosses Above its 10-day MA | 4 | SmarTrend | |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|---|---|---|
| MORPHOSYS | 34,64 | -0,17 % | MorphoSys AG: Veröffentlichung gem. § 26 Abs.1 WpHG mit dem Ziel der europaweiten Verbreitung |
| MEDIGENE | 0,93 | +4,61 % | Medigene: Rating wird erneuert |
| ANTISOMA | 0,017 | 0 % | Antisoma PLC: TR1 Notification of major interest in shares |
| QIAGEN | 14,66 | +1,14 % | QIAGEN Downgraded to Strong Sell |
| AMGEN | 82,00 | +0,79 % | Amgen to Present at the Deutsche Bank 38th Annual Healthcare Conference |
